Inovio completes enrollment of VGX-3100 phase 3 HPV trial (REVEAL 1)
Inovio announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus. June 26, 2019